GB8419489D0
(en)
*
|
1984-07-31 |
1984-09-05 |
Leo Pharm Prod Ltd |
Chemical compounds
|
IL77243A
(en)
*
|
1984-12-21 |
1996-11-14 |
Procter & Gamble |
Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
|
DE3512536A1
(de)
*
|
1985-04-06 |
1986-10-16 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
DE3540150A1
(de)
*
|
1985-11-13 |
1987-05-14 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
DE3623397A1
(de)
*
|
1986-07-11 |
1988-01-14 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
US4963681A
(en)
*
|
1987-07-06 |
1990-10-16 |
Norwich Eaton Pharmaceuticals, Inc. |
Process for synthesis of aminomethylene phosphonoalkylphosphinates
|
IL86951A
(en)
*
|
1987-07-06 |
1996-07-23 |
Procter & Gamble Pharma |
Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
|
US4922007A
(en)
*
|
1989-06-09 |
1990-05-01 |
Merck & Co., Inc. |
Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
|
US5227506A
(en)
*
|
1989-09-06 |
1993-07-13 |
Merck & Co., Inc. |
Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
|
FI83657C
(fi)
*
|
1989-09-08 |
1991-08-12 |
Huhtamaeki Oy |
Foerfarande foer framstaellning av metylenbisfosfonsyror.
|
US5356887A
(en)
*
|
1990-01-31 |
1994-10-18 |
Merck & Co., Inc. |
Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
|
US5019651A
(en)
*
|
1990-06-20 |
1991-05-28 |
Merck & Co., Inc. |
Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
|
GB2248061A
(en)
*
|
1990-09-18 |
1992-03-25 |
Merck & Co Inc |
Amino-hydroxy-alkylidene bis phosphonic acids
|
US5183815A
(en)
*
|
1991-01-22 |
1993-02-02 |
Merck & Co., Inc. |
Bone acting agents
|
IT1247034B
(it)
*
|
1991-06-26 |
1994-12-12 |
Gentili Ist Spa |
Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
|
US6096342A
(en)
*
|
1997-03-12 |
2000-08-01 |
The Procter & Gamble Company |
Dosage forms of risedronate
|
US5270365A
(en)
*
|
1991-12-17 |
1993-12-14 |
Merck & Co., Inc. |
Prevention and treatment of periodontal disease with alendronate
|
TW237386B
(fr)
*
|
1992-04-15 |
1995-01-01 |
Ciba Geigy |
|
US5358941A
(en)
*
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
US6406714B1
(en)
|
1992-12-02 |
2002-06-18 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
US5431920A
(en)
*
|
1993-09-21 |
1995-07-11 |
Merck Frosst, Canada, Inc. |
Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
|
US5591730A
(en)
*
|
1993-10-12 |
1997-01-07 |
The Regents Of The University Of California |
Inhibition of urinary calculi growth
|
US5854227A
(en)
*
|
1994-03-04 |
1998-12-29 |
Hartmann; John F. |
Therapeutic derivatives of diphosphonates
|
US20010007863A1
(en)
*
|
1998-06-18 |
2001-07-12 |
Merck & Co., Inc. |
Wet granulation formulation for bisphosphonic acids
|
US5449819A
(en)
*
|
1994-06-06 |
1995-09-12 |
Merck & Co., Inc. |
Process for removing waste pox, alendronate and its by products
|
JP3411690B2
(ja)
*
|
1994-09-21 |
2003-06-03 |
帝人株式会社 |
局所投与用アレンドロン酸ナトリウム製剤
|
US6008206A
(en)
*
|
1994-09-21 |
1999-12-28 |
Merck & Co., Inc. |
Sodium alendronate preparation for local administration
|
US20010051616A1
(en)
*
|
1995-02-17 |
2001-12-13 |
David B. Karpf |
Method of lessening the risk of vertebral fractures
|
CA2212996A1
(fr)
*
|
1995-02-17 |
1996-08-22 |
Merck & Co., Inc. |
Procede de diminution des risques de fractures osseuses autres que les fractures vertebrales
|
AU713824B2
(en)
*
|
1995-05-12 |
1999-12-09 |
Merck Sharp & Dohme Corp. |
Prevention of tooth loss by the administration of alendronate or its salts
|
WO1996039149A1
(fr)
*
|
1995-06-06 |
1996-12-12 |
Merck & Co., Inc. |
Formulations de sel de monosodium d'alendronate anhydre
|
CA2221844A1
(fr)
*
|
1995-06-06 |
1996-12-12 |
Merck & Co., Inc. |
Preparations d'alendronate disodique
|
CA2223450A1
(fr)
|
1995-06-06 |
1996-12-12 |
Merck & Co., Inc. |
Composition a base de ciment de bisphosphonate permettant d'eviter le relachement aseptique des protheses orthopediques
|
EP1378234A1
(fr)
*
|
1996-05-17 |
2004-01-07 |
MERCK & CO. INC. |
Formulation de bisphosphonate effervescente
|
JP2000511178A
(ja)
*
|
1996-05-17 |
2000-08-29 |
メルク エンド カンパニー インコーポレーテッド |
発泡性ビスホスホネート製剤
|
EP1820497A3
(fr)
*
|
1996-05-17 |
2009-07-22 |
Merck & Co., Inc. |
Formulation de bisphosphonate effervescente
|
NZ334836A
(en)
*
|
1996-10-04 |
2000-11-24 |
Merck & Co Inc |
Liquid alendronate formulations and their use in preventing bone resorption
|
US6376477B2
(en)
|
1996-11-25 |
2002-04-23 |
Merck & Co., Inc. |
Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
US6410782B1
(en)
|
1997-07-09 |
2002-06-25 |
Geange Ltd. |
Diphosphonic acid salts for the treatment of osteoporosis
|
US5994329A
(en)
*
|
1997-07-22 |
1999-11-30 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US6432932B1
(en)
|
1997-07-22 |
2002-08-13 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US6416964B2
(en)
|
1998-01-29 |
2002-07-09 |
Merck & Co., Inc. |
Methods of identifying modulators of kinases responsive to stress
|
US8586781B2
(en)
*
|
1998-04-02 |
2013-11-19 |
Mbc Pharma, Inc. |
Bone targeted therapeutics and methods of making and using the same
|
US7598246B2
(en)
*
|
1998-04-02 |
2009-10-06 |
Mbc Pharma, Inc. |
Bisphosphonate conjugates and methods of making and using the same
|
US6896871B2
(en)
|
1998-04-02 |
2005-05-24 |
Mbc Research, Inc. |
Biphosphonate conjugates and methods of making and using the same
|
US6750340B2
(en)
|
1998-04-02 |
2004-06-15 |
Mbc Research, Inc. |
Bisphosphonate conjugates and methods of making and using the same
|
US6214812B1
(en)
*
|
1998-04-02 |
2001-04-10 |
Mbc Research, Inc. |
Bisphosphonate conjugates and methods of making and using the same
|
WO1999067809A1
(fr)
|
1998-06-24 |
1999-12-29 |
Merck & Co., Inc. |
Compositions et procedes inhibant la resorption osseuse
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6008207A
(en)
*
|
1998-08-13 |
1999-12-28 |
Merck & Co., Inc. |
Anhydrous alendronate monosodium salt formulations
|
EA002739B1
(ru)
|
1998-08-27 |
2002-08-29 |
Тева Фармасьютикал Индастриес Лтд. |
Новые гидратные формы алендроната натрия, способы их получения и фармацевтические композиции
|
US6331533B1
(en)
|
1998-11-16 |
2001-12-18 |
Merck & Co., Inc. |
Method for inhibiting dental resorptive lesions
|
AU770312B2
(en)
*
|
1999-02-17 |
2004-02-19 |
Teva Pharmaceutical Industries Ltd. |
Novel process for preparing alendronic acid
|
US7205404B1
(en)
*
|
1999-03-05 |
2007-04-17 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing prodrugs
|
AR024462A1
(es)
|
1999-07-01 |
2002-10-02 |
Merck & Co Inc |
Tabletas farmaceuticas
|
SE9903345D0
(sv)
*
|
1999-09-17 |
1999-09-17 |
Astra Pharma Prod |
Novel process
|
KR100317935B1
(ko)
*
|
1999-10-20 |
2001-12-22 |
유승필 |
대사성 골질환 치료용 약제조성물 및 이의 제조방법
|
AR021347A1
(es)
*
|
1999-10-20 |
2002-07-17 |
Cipla Ltd |
Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
PE20011061A1
(es)
|
2000-02-01 |
2001-11-20 |
Procter & Gamble |
Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
|
US6562974B2
(en)
|
2000-02-01 |
2003-05-13 |
The Procter & Gamble Company |
Process for making geminal bisphosphonates
|
US6468559B1
(en)
|
2000-04-28 |
2002-10-22 |
Lipocine, Inc. |
Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US6638920B2
(en)
|
2000-07-21 |
2003-10-28 |
Merck & Co., Inc. |
Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
|
US20040038946A1
(en)
*
|
2001-04-27 |
2004-02-26 |
Wilson Lon J. |
Fullerene-based drugs targeted to bone
|
PT1392325E
(pt)
*
|
2001-05-02 |
2006-10-31 |
Novartis Ag |
Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
|
US20030216358A1
(en)
*
|
2001-07-05 |
2003-11-20 |
Muchmore Douglas Boyer |
Method for enhancing bone mineral density gain
|
SK2532004A3
(en)
*
|
2001-12-21 |
2004-11-03 |
Procter & Gamble |
Method for the treatment of bone disorders
|
US20050070504A1
(en)
*
|
2001-12-21 |
2005-03-31 |
The Procter & Gamble Co. |
Risedronate compositions and their methods of use
|
EP1490090A4
(fr)
|
2002-02-22 |
2006-09-20 |
New River Pharmaceuticals Inc |
Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
|
US7488496B2
(en)
*
|
2002-03-06 |
2009-02-10 |
Christer Rosen |
Effervescent compositions comprising bisphosphonates and methods related thereto
|
AU2003226148A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Merck & Co., Inc. |
Method for inhibiting bone resorption with an alendronate and vitamin d formulation
|
ITMI20020908A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione di sodio alendronato
|
RU2387451C2
(ru)
*
|
2002-05-10 |
2010-04-27 |
Ф.Хоффманн-Ля Рош Аг |
Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
|
AU2003233569A1
(en)
*
|
2002-05-17 |
2003-12-02 |
Teva Pharmaceutical Industries Ltd. |
Use of certain diluents for making bisphosphonic acids
|
US20040137058A1
(en)
*
|
2002-07-09 |
2004-07-15 |
Katdare Ashok V. |
Effervescent bisphosphonate formulation
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
RU2315603C2
(ru)
*
|
2002-12-20 |
2008-01-27 |
Ф.Хоффманн-Ля Рош Аг |
Композиция с высокой дозой ибандроната
|
US20040206932A1
(en)
*
|
2002-12-30 |
2004-10-21 |
Abuelyaman Ahmed S. |
Compositions including polymerizable bisphosphonic acids and methods
|
CN1325506C
(zh)
*
|
2003-05-15 |
2007-07-11 |
中国科学院上海药物研究所 |
骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
|
EP2279722B1
(fr)
*
|
2003-08-12 |
2013-05-01 |
3M Innovative Properties Company |
Compositions dentaires d'auto-corrosion et son utilisation
|
MXPA06003063A
(es)
*
|
2003-09-19 |
2006-05-31 |
Pfizer Prod Inc |
Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
|
US20050181043A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Indranil Nandi |
Alendronate salt tablet compositions
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
PL1753395T3
(pl)
|
2004-05-24 |
2011-01-31 |
Warner Chilcott Co Llc |
Stała doustna dojelitowa postać dawkowania bisfosfonianu zawierająca środek chelatujący
|
KR100564628B1
(ko)
*
|
2004-06-16 |
2006-03-28 |
삼성전자주식회사 |
스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
|
EP1784154A1
(fr)
|
2004-07-08 |
2007-05-16 |
3M Innovative Properties Company |
Procédés dentaires, compositions et kits comprenant des teintures sensibles à l"acide
|
US8722760B2
(en)
|
2004-08-11 |
2014-05-13 |
3M Innovative Properties Company |
Self-adhesive compositions including a plurality of acidic compounds
|
US8012949B2
(en)
*
|
2004-10-08 |
2011-09-06 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
|
EP1802641B8
(fr)
*
|
2004-10-08 |
2012-03-07 |
The Board Of Trustees Of The University Of Illinois |
Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
|
WO2007109585A2
(fr)
*
|
2006-03-17 |
2007-09-27 |
The Board Of Trustees Of The University Of Illinois |
Composés de biphosphonates et procédés
|
CN1304401C
(zh)
*
|
2004-12-28 |
2007-03-14 |
浙江工业大学 |
一种阿伦膦酸的制备方法
|
JP2008533173A
(ja)
*
|
2005-03-17 |
2008-08-21 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子ビスホスホネート組成物
|
TWI320783B
(en)
|
2005-04-14 |
2010-02-21 |
Otsuka Pharma Co Ltd |
Heterocyclic compound
|
US20070087052A1
(en)
*
|
2005-10-19 |
2007-04-19 |
Katdare Ashok V |
Effervescent bisphosphonate formulation
|
US8637174B2
(en)
|
2006-02-03 |
2014-01-28 |
Thomas Häring |
Phosphonic acid-containing blends and phosphonic acid-containing polymers
|
MX2009001271A
(es)
*
|
2006-11-21 |
2009-02-11 |
Teikoku Pharma Usa Inc |
Formulaciones inhalantes de bisfosfonato y metodos para el uso de las mismas.
|
US9943465B2
(en)
|
2006-12-13 |
2018-04-17 |
3M Innovative Properties Company |
Methods of using a dental composition having an acidic component and a photobleachable dye
|
US20080182823A1
(en)
*
|
2007-01-26 |
2008-07-31 |
Hidesmasa Katsumi |
Polymer-linked-biophosphonate inhalant formulations and methods for using the same
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
CA2711413A1
(fr)
*
|
2008-02-05 |
2009-08-13 |
Actavis Group Ptc Ehf |
Preparations a base d'alendronate, procede de fabrication et procede d'utilisation associes
|
US7964584B2
(en)
*
|
2008-08-01 |
2011-06-21 |
Dong Wha Pharmaceutical Co., Ltd. |
Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
|
US20100034752A1
(en)
*
|
2008-08-11 |
2010-02-11 |
Toru Hibi |
Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
|
FR2954320B1
(fr)
|
2009-12-17 |
2012-06-15 |
Cll Pharma |
Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
|
US9334300B2
(en)
|
2011-08-01 |
2016-05-10 |
Mbc Pharma, Inc. |
Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
|
GB201200868D0
(en)
|
2012-01-19 |
2012-02-29 |
Depuy Int Ltd |
Bone filler composition
|
JP2017512183A
(ja)
|
2014-02-13 |
2017-05-18 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
US9994600B2
(en)
|
2014-07-02 |
2018-06-12 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and uses therof
|